Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application

Summit Therapeutics (SMMT) shares dropped 13% after the FDA rejected its lung cancer drug application, citing insufficient overall survival benefit. The HARMONi trial showed improved progression-free survival but missed the statistical significance threshold for overall survival. Jefferies noted the decision was anticipated and maintained focus on the upcoming HARMONi-3 trial results.

Original reporting
Published Nov 16, 2026, 3:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application — source image
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The denial eliminates a near‑term revenue opportunity and underscores the importance of overall survival data. The stock's 13% drop reflects immediate market reaction.

02

Market read

Regulatory outcome directly affects Summit's valuation and may influence sentiment toward similar biotech firms awaiting FDA decisions.

03

What to watch

Analyst Jefferies still sees value in the first‑line pipeline; the rejection may be priced in already for the second‑line asset.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech focused on lung cancer therapies. The FDA rejection pertains to its ivonescimab plus chemotherapy regimen for EGFR‑mutated NSCLC.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA issued a complete response letter rejecting Summit Therapeutics' lung cancer drug application, causing the stock to tumble 13%.

Expected impact

downward pressure as investors reassess valuation without the anticipated approval.

Evidence & confidence

Regulatory denial removes a major catalyst; the stock already fell 13% on the news and no alternative near‑term catalyst is evident.

Market effects

Biotech sector may see broader risk‑off pressure on other companies awaiting FDA approvals.

U.S. biotech indices could dip modestly as investors react to the regulatory setback.

Limited to markets with exposure to U.S. biotech stocks; no major macro impact.

Counterpoint

If the company can pivot to its first‑line trial data later in 2026, the stock may recover on new positive data.

Key entities

  • Summit Therapeutics

    Biotech developer of lung cancer therapies.

  • FDA

    U.S. Food and Drug Administration, issuer of the rejection letter.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.